| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Wouter N Leonhard | Q56452933 |
| P2093 | author name string | Dorien J M Peters | |
| Hester Happe | |||
| P2860 | cites work | Cyst expansion and regression in a mouse model of polycystic kidney disease | Q86296609 |
| Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation | Q24317412 | ||
| Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter | Q24323284 | ||
| Generalized lacZ expression with the ROSA26 Cre reporter strain | Q27860837 | ||
| PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein | Q28280639 | ||
| Cardiac defects and renal failure in mice with targeted mutations in Pkd2 | Q28510555 | ||
| A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation | Q28590393 | ||
| Do human chromosomal bands 16p13 and 22q11-13 share ancestral origins? | Q28768483 | ||
| Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease | Q29037884 | ||
| Tubular obstruction leads to progressive proximal tubular injury and atubular glomeruli in polycystic kidney disease | Q30384348 | ||
| Macrophages promote polycystic kidney disease progression | Q33640257 | ||
| Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease | Q33702355 | ||
| Evidence of extraordinary growth in the progressive enlargement of renal cysts | Q33827400 | ||
| Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease | Q33872509 | ||
| Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease | Q33914623 | ||
| An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. | Q34074513 | ||
| Mutations in multiple PKD genes may explain early and severe polycystic kidney disease | Q34228262 | ||
| MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein | Q34386033 | ||
| Genetic variation of DKK3 may modify renal disease severity in ADPKD. | Q34455341 | ||
| Food Restriction Ameliorates the Development of Polycystic Kidney Disease | Q34500619 | ||
| Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis | Q34573001 | ||
| An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease | Q34865335 | ||
| Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis. | Q34870720 | ||
| Polycystin-1 regulates STAT activity by a dual mechanism | Q34977988 | ||
| Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1 | Q35070705 | ||
| Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. | Q35148415 | ||
| Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. | Q35153173 | ||
| M1 and M2 macrophages: the chicken and the egg of immunity | Q35600855 | ||
| Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease | Q35658562 | ||
| Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease | Q35721413 | ||
| Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease | Q35917458 | ||
| Detected renal cysts are tips of the iceberg in adults with ADPKD. | Q36067837 | ||
| Essential role of cleavage of Polycystin-1 at G protein-coupled receptor proteolytic site for kidney tubular structure. | Q36276959 | ||
| Folate-conjugated rapamycin slows progression of polycystic kidney disease | Q36280381 | ||
| Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity | Q36357916 | ||
| A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1 | Q36549183 | ||
| Proximal tubule proliferation is insufficient to induce rapid cyst formation after cilia disruption | Q36638342 | ||
| Src inhibition ameliorates polycystic kidney disease | Q36736752 | ||
| Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease | Q36753925 | ||
| A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease | Q36810726 | ||
| Type of PKD1 mutation influences renal outcome in ADPKD. | Q36880400 | ||
| 2-Deoxy-d-Glucose Ameliorates PKD Progression | Q37051989 | ||
| Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. | Q37092766 | ||
| Renal injury is a third hit promoting rapid development of adult polycystic kidney disease | Q37239858 | ||
| Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury | Q37362069 | ||
| Autosomal dominant polycystic kidney disease--more than a renal disease | Q37991548 | ||
| Translational research in ADPKD: lessons from animal models | Q38241290 | ||
| The polycystic kidney disease-1 promoter is a target of the beta-catenin/T-cell factor pathway | Q38288606 | ||
| Efficient generation and mapping of recessive developmental mutations using ENU mutagenesis | Q38469448 | ||
| Macrophages promote cyst growth in polycystic kidney disease | Q38628997 | ||
| Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease. | Q39884248 | ||
| Overexpression of PKD1 causes polycystic kidney disease | Q41780316 | ||
| Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways | Q42452939 | ||
| PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice | Q42512106 | ||
| Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease | Q42927109 | ||
| Pkd1 haploinsufficiency increases renal damage and induces microcyst formation following ischemia/reperfusion | Q42946110 | ||
| Comprehensive gene expression changes associated with mouse postnatal kidney development | Q44019845 | ||
| Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. | Q45392350 | ||
| Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. | Q45914643 | ||
| Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice | Q46954400 | ||
| A human PKD1 transgene generates functional polycystin-1 in mice and is associated with a cystic phenotype | Q47816764 | ||
| The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. | Q48056738 | ||
| Characterization of the polycystic kidney disease 2 gene promoter. | Q54326165 | ||
| Diet and polycystic kidney disease: A pilot intervention study. | Q55098042 | ||
| The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium | Q55670205 | ||
| Neonatal onset autosomal dominant polycystic kidney disease (ADPKD) in a patient homozygous for aPKD2missense mutation due to uniparental disomy | Q59564351 | ||
| Cyst formation and growth in autosomal dominant polycystic kidney disease | Q69071851 | ||
| More adverse renal prognosis of autosomal dominant polycystic kidney disease in families with primary hypertension | Q71373717 | ||
| Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease | Q77998428 | ||
| Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis | Q79264529 | ||
| Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse model | Q80683730 | ||
| Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease | Q80889030 | ||
| Common regulatory elements in the polycystic kidney disease 1 and 2 promoter regions | Q81527837 | ||
| Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease | Q84409384 | ||
| P433 | issue | 12 | |
| P921 | main subject | autosomal dominant polycystic kidney | Q2732398 |
| autosomal dominant polycystic kidney disease | Q15443105 | ||
| P304 | page(s) | 3530-3538 | |
| P577 | publication date | 2016-08-04 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context | |
| P478 | volume | 27 |
| Q39285003 | Emerging Therapies for Childhood Polycystic Kidney Disease |
| Q91639633 | Four-jointed knock-out delays renal failure in an ADPKD model with kidney injury |
| Q91926245 | Multiple unilateral subcapsular cortical hemorrhagic cystic disease of the kidney: CT and MRI findings and clinical characteristic |
| Q55554153 | Novel long-range regulatory mechanisms controlling PKD2 gene expression. |
| Q88991045 | Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia |
| Q92265492 | Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles |
| Q89518661 | Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective |
| Q93035449 | Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease |
| Q90119264 | Targeting angiogenesis and lymphangiogenesis in kidney disease |
| Q91816627 | The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease |
| Q60301585 | Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective |
Search more.